Suppr超能文献

抗抑郁治疗下的改善时间进程:一种生存分析方法。

Time course of improvement under antidepressant treatment: a survival-analytical approach.

作者信息

Stassen H H, Delini-Stula A, Angst J

机构信息

Psychiatric University Hospital Zurich, Research Department, Switzerland.

出版信息

Eur Neuropsychopharmacol. 1993 Jun;3(2):127-35. doi: 10.1016/0924-977x(93)90264-m.

Abstract

A meta-analysis of an earlier multicenter, double-blind efficacy study comparing placebo, oxaprotiline and amitriptyline was performed in order to test the survival-analytical approach in modelling the onset of improvement and response to treatment with antidepressants. The sample consisted of moderately depressed male (n = 154) and female (n = 275) patients (aged 17-73), diagnosed according to DSM-III criteria for major depression. Of these, 120 were treated with oxaprotiline, 120 with amitriptyline and 189 with placebo. Efficacy criteria were Hamilton Depression (HAMD) and Anxiety (HAMA) and Zung Self-Rating scales. Up to eight ratings over a period of 40 days were available for analysis. The results showed that the sensitivity in discriminating between groups was substantially enhanced through the inclusion of drop-outs and consideration of the effect of time to withdrawal from the study due to lack of improvement. Withdrawal from the trial due to inefficacy occurred earliest under placebo (50% within the first 8 days), whereas less than 40% dropped out within the first 12 days under active treatments. The most interesting and unexpected finding of the analysis was that the time course of improvement among responders was independent of the treatment modality, and thus identical in all three groups. Specifically, the efficacy of any of the given treatments was reflected only by the total number of responders or nonresponders. Once triggered, the time course of recovery from illness becomes identical to that of spontaneous remissions as observed, for example, under placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

为了检验生存分析方法在模拟抗抑郁药治疗改善起效和反应方面的效果,对一项早期多中心、双盲疗效研究进行了荟萃分析,该研究比较了安慰剂、奥沙普明和阿米替林。样本包括根据DSM-III重度抑郁症标准诊断的中度抑郁男性(n = 154)和女性(n = 275)患者(年龄17 - 73岁)。其中,120例接受奥沙普明治疗,120例接受阿米替林治疗,189例接受安慰剂治疗。疗效标准为汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和zung自评量表。在40天的时间里可获得多达八项评分用于分析。结果表明,通过纳入退出者并考虑因改善不足而退出研究的时间影响,区分各组的敏感性显著提高。因无效而退出试验最早出现在安慰剂组(前8天内50%),而在活性治疗组中,前12天内退出者少于40%。该分析最有趣且出乎意料的发现是,反应者改善的时间进程与治疗方式无关,因此在所有三组中相同。具体而言,任何给定治疗的疗效仅由反应者或无反应者的总数反映。一旦触发,疾病恢复的时间进程与例如在安慰剂治疗下观察到的自发缓解的时间进程相同。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验